Systematic development of novel nano lipoidal topical formulations of etodolac and cyclosporine A

Abstract

The present research, entitled Systematic Development of Novel Nano-Lipoidal Topical Formulations of Etodolac and Cyclosporine A, addresses the key drug delivery challenges associated with two useful drugs, Etodolac (ETD) and Cyclosporine A (Cys A). In order to provide the improved carrier-enabled nano-formulation for the treatment of rheumatoid arthritis, uveitis, psoriasis, and dry eye syndrome. A diverse range of lipid-based nanocarriers, including deformable emulsomes, liposomes, complex micelles, and thermo-sensitive organogels, were systematically design and developed to enhance topical drug delivery. The formulations were characterized for micromeritic properties, structural architectural features, drug entrapment and loading traits, followed by extensive in vitro, ex vivo, and in vivo evaluations. The optimized products demonstrated improved local drug concentration, prolonged retention, controlled release behaviour at the target site to exhibit designed pharmacodynamic response. The inventiveness and novelty in the work is attributed to invest uniquely composed and architectured drug-carrier at the nano-scale while employing the bottom-up nano-technological, self-assembling, techniques and using the optimization methods i.e., Quality by Design (QbD). newlineThe work convincingly affirms that nano-lipoidal carriers as promising platforms for enhancing the delivery and therapeutic performance of the chosen drugs. newline newline